Trial Profile
A Randomised, Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Assess the Efficacy and Safety of Single Dose Intranasal GSK1004723 Compared With Placebo in an Allergen Challenge Chamber in Male Subjects With Seasonal Allergic Rhinitis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 1004723 (Primary)
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- 26 May 2012 Planned number of patients is 54 as reported by European Clinical Trials Database.
- 26 May 2012 New source identified and integrated (EudraCT2008-001567-10 European Clinical Trials Database).
- 22 Jan 2009 New trial record.